Cipher Pharmaceuticals Valuation
| CPH Stock | CAD 14.40 0.16 1.12% |
At this time, the firm appears to be overvalued. Cipher Pharmaceuticals shows a prevailing Real Value of C$12.75 per share. The current price of the firm is C$14.4. Our model approximates the value of Cipher Pharmaceuticals from analyzing the firm fundamentals such as Profit Margin of 0.60 %, return on equity of 0.18, and Current Valuation of 423.92 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cipher Pharmaceuticals' valuation include:
Price Book 2.7513 | Enterprise Value 423.9 M | Enterprise Value Ebitda 24.4664 | Price Sales 13.771 | Forward PE 11.9617 |
Overvalued
Today
Please note that Cipher Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Cipher Pharmaceuticals is based on 3 months time horizon. Increasing Cipher Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cipher Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cipher Stock. However, Cipher Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.4 | Real 12.75 | Hype 14.61 |
The intrinsic value of Cipher Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cipher Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cipher Pharmaceuticals helps investors to forecast how Cipher stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cipher Pharmaceuticals more accurately as focusing exclusively on Cipher Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cipher Pharmaceuticals' intrinsic value based on its ongoing forecasts of Cipher Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cipher Pharmaceuticals' closest peers.
Cipher Pharmaceuticals Cash |
|
Cipher Valuation Trend
Knowing Cipher Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Cipher Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Cipher Pharmaceuticals Total Value Analysis
Cipher Pharmaceuticals is currently forecasted to have takeover price of 423.92 M with market capitalization of 364.39 M, debt of 353 K, and cash on hands of 9.25 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Cipher Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
423.92 M | 364.39 M | 353 K | 9.25 M |
Cipher Pharmaceuticals Investor Information
About 42.0% of the company shares are held by company insiders. The book value of Cipher Pharmaceuticals was currently reported as 3.86. The company had not issued any dividends in recent years. Based on the key indicators related to Cipher Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Cipher Pharmaceuticals is performing exceptionally good at this time. It has a great probability to report excellent financial results in December.Cipher Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cipher Pharmaceuticals has an asset utilization ratio of 24.6 percent. This suggests that the Company is making C$0.25 for each dollar of assets. An increasing asset utilization means that Cipher Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Cipher Pharmaceuticals Ownership Allocation
Cipher Pharmaceuticals holds a total of 25.59 Million outstanding shares. Cipher Pharmaceuticals retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cipher Pharmaceuticals Profitability Analysis
The company reported the revenue of 21.16 M. Net Income was 20.38 M with profit before overhead, payroll, taxes, and interest of 16.68 M.About Cipher Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Cipher Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cipher Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Cipher Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Cipher Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cipher Pharmaceuticals. We calculate exposure to Cipher Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cipher Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 17.1 M | 16.3 M | |
| Pretax Profit Margin | 0.60 | 0.63 | |
| Operating Profit Margin | 0.54 | 0.57 | |
| Net Profit Margin | 0.96 | 1.01 | |
| Gross Profit Margin | 0.81 | 0.95 |
Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.